Development of small molecule inhibitors/agonists targeting STING for disease
| Autor: | Mingyue Li, Xiaoling Li, Kaifeng Liu, Liao Cui, Lianxiang Luo, Yongqi Lan, Hui Luo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Innate immune response
0301 basic medicine Small molecule inhibitors Small molecule agonists medicine.medical_treatment RM1-950 Disease Autoimmune Diseases 03 medical and health sciences Drug Delivery Systems 0302 clinical medicine Drug Development Neoplasms medicine Animals Humans Pharmacology Innate immune system business.industry Membrane Proteins Cancer General Medicine Immunotherapy medicine.disease Small molecule eye diseases Sting 030104 developmental biology 030220 oncology & carcinogenesis Stimulator of interferon genes Cancer research Therapeutics. Pharmacology Signal transduction business Signal Transduction |
| Zdroj: | Biomedicine & Pharmacotherapy, Vol 132, Iss, Pp 110945-(2020) |
| ISSN: | 0753-3322 |
| DOI: | 10.1016/j.biopha.2020.110945 |
| Popis: | Cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) -stimulator of interferon genes (STING) signaling pathway is the primary immune response pathway in the cytoplasm. Pharmacological regulation of the STING pathway has good characteristics in both structure and function, which plays a significant role in the immunotherapy of autoimmune diseases, autoinflammatory diseases, and cancer. In this review, we summarized the activation of STING signaling pathway, the STING-related diseases, the development principle and the latest progress of inhibitors and agonists targeting STING. Our review demonstrates that STING signal pathway is a promising drug target, providing effective clues and correct guidance for the discovery of novel small molecule inhibitors/agonists that targeted STING for cancer, autoimmune, and inflammatory diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect